Related Experiment Video

Updated: Jun 9, 2026

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Bendamustine in Metastatic Breast Cancer: An Old Drug in New Design

Cristina Pirvulescu1, Gunter von Minckwitz, Sibylle Loibl

  • 1German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany.

Breast Care (Basel, Switzerland)
|September 9, 2010
PubMed

Insights

Bendamustine, an alkylating agent, shows cytotoxic activity in metastatic breast cancer. Further investigation into bendamustine combinations may improve survival and reduce toxicity in advanced breast cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced breast cancer treatment aims to prolong survival and manage symptoms.
  • Current cytotoxic agents offer limited survival benefits for metastatic breast cancer.
  • Novel therapeutic strategies, including targeted agents, are under investigation.

Purpose of the Study:

  • To review the antitumor activity, toxicity, pharmacokinetics, and clinical applications of bendamustine.
  • To evaluate bendamustine as a cytotoxic agent for metastatic breast cancer.
  • To explore bendamustine in anthracycline-free combinations to mitigate cardiac toxicity.

Main Methods:

  • Literature review of bendamustine's properties and clinical data.
  • Analysis of preclinical and clinical studies on bendamustine in breast cancer.
  • Assessment of bendamustine's efficacy and safety profile.

Main Results:

  • Bendamustine exhibits cytotoxic activity against various solid tumors.
  • Bendamustine's pharmacokinetic profile supports its clinical use.
  • Potential for bendamustine in combination therapies, particularly anthracycline-free regimens, is highlighted.

Conclusions:

  • Bendamustine is a promising cytotoxic agent for metastatic breast cancer.
  • Further research into bendamustine-based combinations may enhance treatment outcomes.
  • Bendamustine offers a potential alternative for patients with advanced breast cancer, possibly reducing cardiotoxicity.

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...